Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Cooler February inflation doesn’t mean Fed will lower rates, promising obesity drug could challenge Novo Nordisk and Eli ...

Morgans analyst Scott Power notes there's a risk-off sentiment among investors as ASX health stocks fall again this week.

By 2020, Chouinard’s discomfort with his ownership of the lucrative outdoor apparel brand was ramping up. While Patagonia has ...

Prostate cancer remains one of the most commonly diagnosed cancersworldwide, with 1.4 million new cases and over 375,000 ...

Detailed price information for Praxis Precision Medicines Inc (PRAX-Q) from The Globe and Mail including charting and trades.

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Learn the value of AI transformation and how three Microsoft AI platforms, including Microsoft Copilot, boost productivity in this Microsoft Cloud blog.